|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
3-phenoxybenzylalcohol inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein] |
CTD |
PMID:33049310 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
increases abundance |
ISO |
CYP2C19 protein results in increased abundance of 3-phenoxybenzylalcohol |
CTD |
PMID:24548679 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases abundance |
ISO |
CYP3A4 protein results in increased abundance of 3-phenoxybenzylalcohol |
CTD |
PMID:24548679 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions decreases expression |
ISO |
3-phenoxybenzylalcohol binds to and results in increased activity of ESR1 protein 3-phenoxybenzylalcohol results in decreased expression of ESR1 mRNA |
CTD |
PMID:16395479 PMID:20397420 PMID:33049310 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
3-phenoxybenzylalcohol binds to and results in increased activity of ESR2 protein |
CTD |
PMID:33049310 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO EXP |
3-phenoxybenzylalcohol binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:31538121 PMID:33049310 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
3-phenoxybenzylalcohol binds to and results in increased activity of PPARA protein |
CTD |
PMID:31538121 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
3-phenoxybenzylalcohol binds to and results in increased activity of PPARG protein |
CTD |
PMID:33049310 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
3-phenoxybenzylalcohol results in increased expression of TFF1 mRNA |
CTD |
PMID:20397420 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases glucuronidation increases chemical synthesis increases abundance multiple interactions |
ISO |
CYP3A4 protein results in increased glucuronidation of 1-hydroxymethylmidazolam CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam CYP3A4 protein results in increased abundance of 1-hydroxymethylmidazolam [[3-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[5-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[6-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[6-methylflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[7-hydroxyflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[alpha-naphthoflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[artemetin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[beta-Naphthoflavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[chrysin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[eupatilin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[flavone results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[galangin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[nobiletin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[sinensetin analog results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[sinensetin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[tangeretin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [CYP3A4 protein results in increased glucuronidation of 1-hydroxymethylmidazolam] which results in increased abundance of 1-hydroxymethylmidazolam glucuronide; [CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased abundance of 1-hydroxymethylmidazolam; [CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [Ketoconazole results in decreased activity of CYP3A4 protein] which results in decreased chemical synthesis of 1-hydroxymethylmidazolam; [L 754394 results in decreased activity of CYP3A4 protein] which results in decreased chemical synthesis of 1-hydroxymethylmidazolam; acacetin promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Apigenin promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 1-hydroxymethylmidazolam]; diosmetin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; flavanone promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; flavone promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; galangin promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased abundance of 1-hydroxymethylmidazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Luteolin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]]; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Verapamil inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam] |
CTD |
PMID:10997946 PMID:12401345 PMID:12695342 PMID:18191104 PMID:20233841 PMID:21053930 PMID:21915887 PMID:23850985 PMID:26958860 PMID:27485346 PMID:30087611 PMID:31756459 PMID:34189909 More...
|
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases chemical synthesis multiple interactions |
ISO |
CYP3A5 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam [CYP3A5 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; erdafitinib inhibits the reaction [[CYP3A5 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam] |
CTD |
PMID:18191104 PMID:26958860 PMID:34189909 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Tspo |
translocator protein |
affects binding |
EXP |
1-hydroxymethylmidazolam binds to TSPO protein; 1-hydroxymethylmidazolam metabolite binds to TSPO protein |
CTD |
PMID:7603229 |
|
NCBI chr 7:114,720,188...114,730,450
Ensembl chr 7:114,720,188...114,730,450
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[CYP3A4 protein results in increased glucuronidation of 1-hydroxymethylmidazolam] which results in increased abundance of 1-hydroxymethylmidazolam glucuronide |
CTD |
PMID:27485346 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
2-phenyl-2-propanol binds to and results in decreased activity of THRB protein |
CTD |
PMID:27633901 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity |
EXP |
3-methylbenzyl alcohol results in decreased activity of CYP2B1 protein |
CTD |
PMID:12791539 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp4b1 |
cytochrome P450, family 4, subfamily b, polypeptide 1 |
decreases activity |
EXP |
3-methylbenzyl alcohol results in decreased activity of CYP4B1 protein |
CTD |
PMID:12791539 |
|
NCBI chr 5:129,139,019...129,176,860
Ensembl chr 5:129,139,038...129,156,348
|
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
multiple interactions |
ISO |
[CYP2C55 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide |
CTD |
PMID:30503582 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
multiple interactions |
ISO |
[CYP2C19 protein results in increased hydroxylation of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide |
CTD |
PMID:30500380 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
|
G |
Atm |
ATM serine/threonine kinase |
decreases methylation |
ISO |
5-hydroxymethylcytosine results in decreased methylation of ATM gene |
CTD |
PMID:30990028 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Cmahp |
cytidine monophospho-N-acetylneuraminic acid hydroxylase, pseudogene |
multiple interactions |
ISO |
[bisphenol A results in decreased methylation of CMAH intron] which results in decreased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:30044229 |
|
NCBI chr17:40,557,161...40,642,350
Ensembl chr17:40,583,667...40,642,275
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
DNMT1 protein promotes the reaction [bis(4-hydroxyphenyl)sulfone results in decreased abundance of 5-hydroxymethylcytosine]; DNMT1 protein promotes the reaction [bisphenol A results in decreased abundance of 5-hydroxymethylcytosine] |
CTD |
PMID:32105160 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
multiple interactions |
ISO |
DNMT3A protein promotes the reaction [bis(4-hydroxyphenyl)sulfone results in decreased abundance of 5-hydroxymethylcytosine]; DNMT3A protein promotes the reaction [bisphenol A results in decreased abundance of 5-hydroxymethylcytosine] |
CTD |
PMID:32105160 |
|
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions decreases abundance |
ISO |
ESR1 protein promotes the reaction [bis(4-hydroxyphenyl)sulfone results in decreased abundance of 5-hydroxymethylcytosine]; ESR1 protein promotes the reaction [bisphenol A results in decreased abundance of 5-hydroxymethylcytosine] ESR1 protein results in decreased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:32105160 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Ftl1 |
ferritin light chain 1 |
multiple interactions |
ISO |
[Chloranil results in increased abundance of 5-hydroxymethylcytosine] which results in increased expression of FTL mRNA |
CTD |
PMID:24214992 |
|
NCBI chr 1:95,936,390...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[hydroquinone affects the methylation of GCLC promoter] which results in increased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:23940045 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gnas |
GNAS complex locus |
multiple interactions |
ISO |
[bisphenol A results in increased methylation of GNAS intron] which results in increased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:30044229 |
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Grb10 |
growth factor receptor bound protein 10 |
multiple interactions |
ISO |
[bisphenol A results in increased methylation of GRB10 intron] which results in increased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:30044229 |
|
NCBI chr14:86,495,054...86,602,815
Ensembl chr14:86,495,054...86,602,806
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
decreases abundance |
ISO |
IDH2 protein mutant form results in decreased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Kcnq1 |
potassium voltage-gated channel subfamily Q member 1 |
multiple interactions |
ISO |
[bisphenol A results in decreased methylation of KCNQ1 intron] which results in decreased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:30044229 |
|
NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669
|
|
G |
Klf14 |
KLF transcription factor 14 |
multiple interactions |
ISO |
[bisphenol A results in decreased methylation of KLF14 exon] which results in decreased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:30044229 |
|
NCBI chr 4:59,554,011...59,556,933
Ensembl chr 4:59,554,011...59,556,933
|
|
G |
Pde10a |
phosphodiesterase 10A |
multiple interactions |
ISO |
[bisphenol A results in increased methylation of PDE10A intron] which results in increased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:30044229 |
|
NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:51,770,132...52,216,563
|
|
G |
Pde4d |
phosphodiesterase 4D |
multiple interactions |
ISO |
[bisphenol A results in increased methylation of PDE4D exon] which results in increased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:30044229 |
|
NCBI chr 2:40,014,933...41,529,190
Ensembl chr 2:40,019,933...41,525,884
|
|
G |
Plagl1 |
PLAG1 like zinc finger 1 |
multiple interactions |
ISO |
[bisphenol A results in increased methylation of PLAGL1 exon] which results in increased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:30044229 |
|
NCBI chr 1:7,477,295...7,517,229
Ensembl chr 1:7,477,177...7,517,228
|
|
G |
Ppp1r9a |
protein phosphatase 1, regulatory subunit 9A |
multiple interactions |
ISO |
[bisphenol A results in decreased methylation of PPP1R9A intron] which results in decreased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:30044229 |
|
NCBI chr 4:32,970,501...33,292,360
Ensembl chr 4:33,024,450...33,286,907
|
|
G |
Sfn |
stratifin |
multiple interactions |
ISO |
[hydroquinone affects the methylation of SFN promoter] which results in increased abundance of 5-hydroxymethylcytosine |
CTD |
PMID:23940045 |
|
Ensembl chr 5:145,826,201...145,831,314
|
|
G |
Tet1 |
tet methylcytosine dioxygenase 1 |
multiple interactions |
ISO |
TET1 protein affects the reaction [2,3,5,6-tetrachlorohydroquinone results in increased chemical synthesis of 5-hydroxymethylcytosine]; TET1 protein affects the reaction [Chloranil results in increased chemical synthesis of 5-hydroxymethylcytosine] |
CTD |
PMID:24214992 |
|
NCBI chr20:25,761,042...25,840,926
Ensembl chr20:25,768,120...25,833,052
|
|
G |
Tet2 |
tet methylcytosine dioxygenase 2 |
multiple interactions increases abundance |
ISO |
TET2 protein affects the reaction [2,3,5,6-tetrachlorohydroquinone results in increased chemical synthesis of 5-hydroxymethylcytosine]; TET2 protein affects the reaction [Chloranil results in increased chemical synthesis of 5-hydroxymethylcytosine] bis(4-hydroxyphenyl)sulfone promotes the reaction [TET2 protein results in increased abundance of 5-hydroxymethylcytosine]; bisphenol A promotes the reaction [TET2 protein results in increased abundance of 5-hydroxymethylcytosine]; TET2 protein inhibits the reaction [bis(4-hydroxyphenyl)sulfone results in decreased abundance of 5-hydroxymethylcytosine]; TET2 protein inhibits the reaction [bisphenol A results in decreased abundance of 5-hydroxymethylcytosine] |
CTD |
PMID:24214992 PMID:32105160 |
|
NCBI chr 2:221,988,645...222,072,813
Ensembl chr 2:221,988,645...222,072,534
|
|
G |
Ubc |
ubiquitin C |
multiple interactions |
ISO |
[Chloranil results in increased abundance of 5-hydroxymethylcytosine] which results in increased expression of UBC mRNA |
CTD |
PMID:24214992 |
|
NCBI chr12:31,238,889...31,243,924
Ensembl chr12:31,239,152...31,243,925
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
aloe emodin inhibits the reaction [1-Methyl-3-isobutylxanthine results in decreased expression of ADIPOQ mRNA] |
CTD |
PMID:22645054 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
decreases activity |
ISO |
aloe emodin results in decreased activity of AKR1B10 protein |
CTD |
PMID:35065925 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases activity |
ISO |
aloe emodin results in decreased activity of AKR1C3 protein |
CTD |
PMID:35065925 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
aloe emodin results in increased expression of ATF3 mRNA |
CTD |
PMID:22210228 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
aloe emodin results in increased expression of BAX protein |
CTD |
PMID:19928967 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
aloe emodin results in decreased expression of BCL2 mRNA; aloe emodin results in decreased expression of BCL2 protein |
CTD |
PMID:19928967 PMID:22210228 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
increases expression increases activity multiple interactions increases cleavage |
ISO |
aloe emodin results in increased expression of CASP3 protein modified form aloe emodin results in increased activity of CASP3 protein [Fluorouracil co-treated with aloe emodin] affects the expression of CASP3; Fluorouracil promotes the reaction [aloe emodin results in increased expression of CASP3 protein modified form] aloe emodin results in increased cleavage of CASP3 protein |
CTD |
PMID:19928967 PMID:22210228 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases expression increases activity multiple interactions |
ISO |
aloe emodin results in increased expression of CASP8 protein modified form aloe emodin results in increased activity of CASP8 protein [Fluorouracil co-treated with aloe emodin] affects the expression of CASP8; Fluorouracil promotes the reaction [aloe emodin results in increased expression of CASP8 protein modified form] |
CTD |
PMID:19928967 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity increases expression multiple interactions |
ISO |
aloe emodin results in increased activity of CASP9 protein aloe emodin results in increased expression of CASP9 protein modified form [Fluorouracil co-treated with aloe emodin] affects the expression of CASP9; Fluorouracil promotes the reaction [aloe emodin results in increased expression of CASP9 protein modified form] |
CTD |
PMID:19928967 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cbr1 |
carbonyl reductase 1 |
decreases activity |
ISO |
aloe emodin results in decreased activity of CBR1 protein |
CTD |
PMID:35065925 |
|
NCBI chr11:32,860,618...32,862,981
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G |
Cbr1l1 |
carbonyl reductase 1 like 1 |
decreases activity |
ISO |
aloe emodin results in decreased activity of CBR1 protein |
CTD |
PMID:35065925 |
|
NCBI chr11:32,876,563...32,884,234
|
|
G |
Cycs |
cytochrome c, somatic |
increases expression |
ISO |
aloe emodin results in increased expression of CYCS protein |
CTD |
PMID:19928967 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
aloe emodin results in decreased activity of CYP1A1 protein |
CTD |
PMID:27633141 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
aloe emodin results in decreased activity of CYP1A2 protein |
CTD |
PMID:27633141 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
aloe emodin results in decreased activity of CYP1B1 protein |
CTD |
PMID:27633141 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases chemical synthesis |
ISO |
[CYP2B6 protein results in increased metabolism of chrysophanic acid] which results in increased chemical synthesis of aloe emodin CYP2B6 protein results in increased chemical synthesis of aloe emodin |
CTD |
PMID:29698620 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases chemical synthesis |
ISO |
[CYP3A4 protein results in increased metabolism of chrysophanic acid] which results in increased chemical synthesis of aloe emodin CYP3A4 protein results in increased chemical synthesis of aloe emodin |
CTD |
PMID:29698620 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
aloe emodin results in increased expression of DDIT3 mRNA; aloe emodin results in increased expression of DDIT3 protein |
CTD |
PMID:22210228 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation |
ISO |
aloe emodin results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:22210228 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions |
ISO |
aloe emodin inhibits the reaction [1-Methyl-3-isobutylxanthine results in increased expression of FABP4 mRNA] |
CTD |
PMID:22645054 |
|
NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fadd |
Fas associated via death domain |
multiple interactions |
ISO |
aloe emodin results in increased expression of and affects the localization of FADD protein |
CTD |
PMID:19928967 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
aloe emodin results in increased expression of FAS protein |
CTD |
PMID:19928967 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
aloe emodin results in increased expression of FASLG protein |
CTD |
PMID:19928967 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
aloe emodin results in increased expression of HSPA5 mRNA; aloe emodin results in increased expression of HSPA5 protein |
CTD |
PMID:22210228 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
aloe emodin inhibits the reaction [1-Methyl-3-isobutylxanthine results in increased expression of LPL mRNA] |
CTD |
PMID:22645054 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Nat1 |
N-acetyltransferase 1 |
multiple interactions decreases expression |
ISO |
aloe emodin results in decreased expression of and results in decreased activity of NAT1 protein aloe emodin results in decreased expression of NAT1 mRNA |
CTD |
PMID:16314733 |
|
NCBI chr16:22,218,217...22,238,516
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
aloe emodin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA] |
CTD |
PMID:19352036 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
aloe emodin inhibits the reaction [1-Methyl-3-isobutylxanthine results in increased expression of PPARG mRNA] |
CTD |
PMID:22645054 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
aloe emodin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA] |
CTD |
PMID:19352036 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Retn |
resistin |
multiple interactions |
ISO |
aloe emodin inhibits the reaction [1-Methyl-3-isobutylxanthine results in increased expression of RETN mRNA] |
CTD |
PMID:22645054 |
|
NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
decreases activity |
ISO |
aloe emodin results in decreased activity of SULT1A1 protein |
CTD |
PMID:27633141 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Sult1e1 |
sulfotransferase family 1E member 1 |
decreases activity |
ISO |
aloe emodin results in decreased activity of SULT1E1 protein |
CTD |
PMID:27633141 |
|
NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO |
aloe emodin inhibits the reaction [1-Methyl-3-isobutylxanthine results in increased expression of TNF mRNA] aloe emodin results in increased expression of TNF protein |
CTD |
PMID:19928967 PMID:22645054 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression |
ISO |
aloe emodin results in increased expression of TNFRSF1A protein |
CTD |
PMID:19928967 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
increases expression |
ISO |
aloe emodin results in increased expression of TNFRSF1B protein |
CTD |
PMID:19928967 |
|
NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
aloe emodin results in increased expression of TP53 protein |
CTD |
PMID:19928967 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tradd |
TNFRSF1A-associated via death domain |
multiple interactions |
ISO |
aloe emodin results in increased expression of and affects the localization of TRADD protein |
CTD |
PMID:19928967 |
|
NCBI chr19:33,136,148...33,142,714
Ensembl chr19:33,136,138...33,142,638
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of aloe emodin |
CTD |
PMID:24854283 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Xbp1 |
X-box binding protein 1 |
increases splicing |
ISO |
aloe emodin results in increased splicing of XBP1 mRNA |
CTD |
PMID:22210228 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
increases expression |
ISO |
benzyl acetate results in increased expression of ENPP2 mRNA; benzyl acetate results in increased expression of ENPP2 protein |
CTD |
PMID:22952646 |
|
NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression |
ISO |
benzyl acetate results in increased expression of MMP9 mRNA; benzyl acetate results in increased expression of MMP9 protein |
CTD |
PMID:22952646 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
multiple interactions |
ISO |
benzyl acetate results in increased cleavage of and results in increased activity of PPP3CA protein |
CTD |
PMID:22952646 |
|
NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974
|
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
increases oxidation |
ISO |
AKR1B1 protein results in increased oxidation of Benzyl Alcohol |
CTD |
PMID:17194029 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Benzyl Alcohol results in increased expression of IL1A protein |
CTD |
PMID:19878710 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
increases expression |
ISO |
Benzyl Alcohol results in increased expression of LIF protein |
CTD |
PMID:19878710 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
increases sulfation |
ISO |
SULT1A1 protein results in increased sulfation of Benzyl Alcohol |
CTD |
PMID:26663444 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Sult1b1 |
sulfotransferase family 1B member 1 |
increases sulfation |
ISO |
SULT1B1 protein results in increased sulfation of Benzyl Alcohol |
CTD |
PMID:26663444 |
|
NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483
|
|
G |
Ugt2b17 |
UDP glucuronosyltransferase family 2 member B17 |
increases glucuronidation |
EXP |
UGT2B1 protein results in increased glucuronidation of Benzyl Alcohol |
CTD |
PMID:8302279 |
|
NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
|
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
benzyl benzoate results in increased expression of ATF3 mRNA |
CTD |
PMID:27965148 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
benzyl benzoate results in increased expression of CD86 protein |
CTD |
PMID:29540657 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
benzyl benzoate inhibits the reaction [Estradiol binds to ESR1 protein] |
CTD |
PMID:19338011 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
benzyl benzoate inhibits the reaction [Estradiol binds to ESR2 protein] |
CTD |
PMID:19338011 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity |
ISO |
benzyl benzoate results in decreased activity of MAOA protein |
CTD |
PMID:27270453 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Maob |
monoamine oxidase B |
decreases activity |
ISO |
benzyl benzoate results in decreased activity of MAOB protein |
CTD |
PMID:27270453 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Nefh |
neurofilament heavy chain |
affects expression |
EXP |
benzyl benzoate affects the expression of NEFH mRNA |
CTD |
PMID:22954530 |
|
NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
benzyl benzoate results in increased expression of TFF1 mRNA |
CTD |
PMID:19338011 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
ISO |
benzylparaben results in increased expression of ADIPOQ mRNA |
CTD |
PMID:22956630 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Afp |
alpha-fetoprotein |
affects binding |
EXP |
benzylparaben binds to AFP protein |
CTD |
PMID:23013281 PMID:25349334 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases expression |
ISO |
benzylparaben results in increased expression of CEBPA mRNA |
CTD |
PMID:22956630 PMID:27659731 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
benzylparaben binds to and results in increased activity of ESR1 protein |
CTD |
PMID:23220609 PMID:23567241 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
benzylparaben binds to and results in increased activity of ESR2 protein |
CTD |
PMID:23567241 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Esrrg |
estrogen-related receptor gamma |
multiple interactions |
ISO |
benzylparaben inhibits the reaction [afimoxifene inhibits the reaction [ESRRG protein binds to NCOA2 protein]] |
CTD |
PMID:23583298 |
|
NCBI chr13:99,167,656...99,788,016
Ensembl chr13:99,564,669...99,783,397
|
|
G |
Faah |
fatty acid amide hydrolase |
decreases activity |
ISO EXP |
benzylparaben results in decreased activity of FAAH protein |
CTD |
PMID:27659731 |
|
NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression |
ISO |
benzylparaben results in increased expression of FABP4 mRNA |
CTD |
PMID:22956630 PMID:27659731 |
|
NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
benzylparaben results in increased expression of FASN mRNA |
CTD |
PMID:22956630 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Lep |
leptin |
increases expression decreases expression |
ISO |
benzylparaben results in increased expression of LEP mRNA benzylparaben results in decreased expression of LEP mRNA |
CTD |
PMID:22956630 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
benzylparaben inhibits the reaction [afimoxifene inhibits the reaction [ESRRG protein binds to NCOA2 protein]] |
CTD |
PMID:23583298 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases expression |
ISO |
benzylparaben results in increased expression of NR1I2 mRNA |
CTD |
PMID:31472229 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO |
benzylparaben results in increased activity of NR1I3 protein |
CTD |
PMID:28927721 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression |
EXP |
benzylparaben results in increased expression of PPARA mRNA |
CTD |
PMID:31472229 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression increases activity |
ISO |
benzylparaben results in increased expression of PPARG mRNA benzylparaben results in increased activity of PPARG protein |
CTD |
PMID:22956630 PMID:27659731 PMID:28527915 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Shbg |
sex hormone binding globulin |
affects binding |
ISO |
benzylparaben binds to SHBG protein |
CTD |
PMID:25349334 |
|
NCBI chr10:54,332,939...54,350,409
Ensembl chr10:54,332,941...54,351,057
|
|
|
G |
A4galt |
alpha 1,4-galactosyltransferase (P blood group) |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of A4GALT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:114,368,525...114,392,872
Ensembl chr 7:114,368,276...114,396,071
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of ABCC3 mRNA |
CTD |
PMID:26519955 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ABCG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of ACACA protein |
CTD |
PMID:26820058 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of ACOT1 mRNA |
CTD |
PMID:26519955 |
|
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of ADAMTS1 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of ADIPOQ mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of ADIPOQ protein; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]] butylbenzyl phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; butylbenzyl phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]; butylbenzyl phthalate promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein] |
CTD |
PMID:26820058 PMID:28595985 PMID:31016361 PMID:32407875 PMID:34864131 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions affects localization affects activity increases expression |
ISO |
3',4'-dimethoxyflavone inhibits the reaction [butylbenzyl phthalate results in increased expression of AHR mRNA]; 3',4'-dimethoxyflavone inhibits the reaction [butylbenzyl phthalate results in increased expression of AHR protein]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of ARNT mRNA]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of ARNT protein]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP1B1 mRNA]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP1B1 protein]; butylbenzyl phthalate binds to and results in increased activity of AHR protein; butylbenzyl phthalate promotes the reaction [AHR protein binds to ARNT protein]; butylbenzyl phthalate promotes the reaction [AHR protein binds to CYP1B1 promoter] butylbenzyl phthalate affects the localization of AHR protein butylbenzyl phthalate affects the activity of AHR protein butylbenzyl phthalate results in increased expression of AHR mRNA; butylbenzyl phthalate results in increased expression of AHR protein |
CTD |
PMID:18294747 PMID:22138065 PMID:23220035 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ak5 |
adenylate kinase 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of AK5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:241,397,297...241,581,483
Ensembl chr 2:241,397,297...241,581,458
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation affects phosphorylation increases phosphorylation multiple interactions |
ISO EXP |
butylbenzyl phthalate results in decreased phosphorylation of AKT1 protein butylbenzyl phthalate affects the phosphorylation of AKT1 protein butylbenzyl phthalate results in increased phosphorylation of AKT1 protein HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:22552774 PMID:29864457 PMID:31319113 PMID:33395283 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
increases phosphorylation |
EXP |
butylbenzyl phthalate results in increased phosphorylation of AKT2 protein |
CTD |
PMID:31319113 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:30768133 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ALDOC mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Amh |
anti-Mullerian hormone |
increases expression multiple interactions |
EXP |
butylbenzyl phthalate results in increased expression of AMH mRNA; butylbenzyl phthalate results in increased expression of AMH protein [butylbenzyl phthalate co-treated with 4-vinyl-1-cyclohexene dioxide] results in decreased expression of AMH mRNA; [butylbenzyl phthalate co-treated with Dibutyl Phthalate] results in decreased expression of AMH mRNA; butylbenzyl phthalate promotes the reaction [4-vinyl-1-cyclohexene dioxide results in decreased expression of AMH protein] |
CTD |
PMID:29969652 PMID:31319113 |
|
NCBI chr 7:8,906,776...8,909,184
Ensembl chr 7:8,906,836...8,909,282
|
|
G |
Ar |
androgen receptor |
multiple interactions affects activity affects binding decreases activity |
ISO EXP |
butylbenzyl phthalate inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; butylbenzyl phthalate inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; butylbenzyl phthalate inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; butylbenzyl phthalate inhibits the reaction [Stanozolol binds to and results in increased activity of AR protein] butylbenzyl phthalate affects the activity of AR protein butylbenzyl phthalate binds to AR protein butylbenzyl phthalate results in decreased activity of AR protein |
CTD |
PMID:9846162 PMID:14565775 PMID:15840436 PMID:18294747 PMID:20943248 PMID:28571686 PMID:29162470 PMID:33049310 More...
|
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
increases expression multiple interactions |
ISO |
butylbenzyl phthalate results in increased expression of ARNT mRNA; butylbenzyl phthalate results in increased expression of ARNT protein 3',4'-dimethoxyflavone inhibits the reaction [butylbenzyl phthalate results in increased expression of ARNT mRNA]; 3',4'-dimethoxyflavone inhibits the reaction [butylbenzyl phthalate results in increased expression of ARNT protein]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of ARNT mRNA]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of ARNT protein]; butylbenzyl phthalate promotes the reaction [AHR protein binds to ARNT protein] |
CTD |
PMID:22138065 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Arnt2 |
aryl hydrocarbon receptor nuclear translocator 2 |
decreases expression multiple interactions |
ISO EXP |
butylbenzyl phthalate results in decreased expression of ARNT2 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ARNT2 mRNA 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [butylbenzyl phthalate results in decreased expression of ARNT2 mRNA] |
CTD |
PMID:21771643 PMID:31199487 |
|
NCBI chr 1:138,236,235...138,392,868
Ensembl chr 1:138,189,940...138,393,153
|
|
G |
Astn1 |
astrotactin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ASTN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:70,537,423...70,855,440
Ensembl chr13:70,537,703...70,855,440
|
|
G |
Astn2 |
astrotactin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ASTN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:78,758,142...79,744,021
Ensembl chr 5:78,758,142...79,748,273
|
|
G |
Atm |
ATM serine/threonine kinase |
increases expression multiple interactions |
ISO |
butylbenzyl phthalate results in increased expression of ATM protein ATM protein affects the reaction [butylbenzyl phthalate results in increased expression of ZEB1 protein] |
CTD |
PMID:31212022 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of ATP1A1 mRNA |
CTD |
PMID:19560483 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ATP1A3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BAX mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BCAT1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:177,964,834...178,046,573
Ensembl chr 4:177,964,834...178,046,597
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases methylation increases expression |
ISO EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of BCL2 mRNA butylbenzyl phthalate results in decreased methylation of BCL2 promoter butylbenzyl phthalate results in increased expression of BCL2 mRNA |
CTD |
PMID:28013214 PMID:35487445 PMID:35762964 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bend6 |
BEN domain containing 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BEND6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:36,081,033...36,135,309
Ensembl chr 9:36,081,484...36,135,228
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of BMP6 mRNA |
CTD |
PMID:19560483 |
|
NCBI chr17:26,318,121...26,469,034
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Bpgm |
bisphosphoglycerate mutase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BPGM mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:63,139,730...63,168,581
Ensembl chr 4:63,140,018...63,168,581
|
|
G |
Cacng7 |
calcium voltage-gated channel auxiliary subunit gamma 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CACNG7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:65,800,820...65,831,165
Ensembl chr 1:65,800,355...65,831,006
|
|
G |
Cadm3 |
cell adhesion molecule 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CADM3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:85,786,482...85,817,412
Ensembl chr13:85,786,483...85,817,749
|
|
G |
Cadps |
calcium dependent secretion activator |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CADPS mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:12,289,803...12,742,786
Ensembl chr15:12,290,262...12,742,779
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CAMK4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression |
ISO |
[Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with 4-nonylphenol co-treated with 4-tert-octylphenol] results in increased expression of and results in increased activity of CASP3 protein; butylbenzyl phthalate results in increased expression of and results in increased activity of CASP3 protein butylbenzyl phthalate results in increased expression of CASP3 protein alternative form |
CTD |
PMID:23220035 PMID:29029336 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CASP8 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CAT mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases methylation increases expression |
ISO |
MIR19A mRNA affects the reaction [butylbenzyl phthalate results in increased expression of CCND1 protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in increased expression of CCND1 protein]; MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of CCND1 protein] butylbenzyl phthalate results in decreased methylation of CCND1 promoter butylbenzyl phthalate results in increased expression of CCND1 mRNA; butylbenzyl phthalate results in increased expression of CCND1 protein |
CTD |
PMID:29864457 PMID:30243731 PMID:35487445 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CCND2 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of CDH1 protein |
CTD |
PMID:22552774 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CDK4 mRNA |
CTD |
PMID:35762964 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression multiple interactions |
ISO EXP |
butylbenzyl phthalate results in decreased expression of CDKN1A mRNA; butylbenzyl phthalate results in decreased expression of CDKN1A protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CDKN1A mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of CDKN1A mRNA] MIR19A mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of CDKN1A protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of CDKN1A protein]; MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in decreased expression of CDKN1A protein] |
CTD |
PMID:29864457 PMID:30243731 PMID:33316053 PMID:35762964 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions increases methylation decreases expression |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of CDKN2A mRNA butylbenzyl phthalate results in increased methylation of CDKN2A promoter butylbenzyl phthalate results in decreased expression of CDKN2A mRNA |
CTD |
PMID:28013214 PMID:35487445 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of CEBPA mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of CEBPA protein; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]] |
CTD |
PMID:26820058 PMID:28595985 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Celsr3 |
cadherin, EGF LAG seven-pass G-type receptor 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CELSR3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:109,530,597...109,558,360
Ensembl chr 8:109,530,641...109,558,354
|
|
G |
Cfd |
complement factor D |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of CFD mRNA |
CTD |
PMID:26820058 |
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions |
ISO |
butylbenzyl phthalate inhibits the reaction [CGA protein results in increased secretion of Dinoprostone]; butylbenzyl phthalate inhibits the reaction [CGA protein results in increased secretion of Progesterone] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of EDN2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of MMP9 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PGR mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PLAT mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of CDKN1A mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of IL6 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PTGS2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINB2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINE1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of TIMP1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of WNT4 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP14 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP16 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of SLCO2A1 mRNA] |
CTD |
PMID:25016925 PMID:33316053 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Chga |
chromogranin A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CHGA mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398
|
|
G |
Chgb |
chromogranin B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CHGB mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:120,043,824...120,057,169
Ensembl chr 3:120,043,738...120,057,166
|
|
G |
Cited1 |
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CITED1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:67,350,376...67,355,072
Ensembl chr X:67,350,373...67,355,162
|
|
G |
Clstn3 |
calsyntenin 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CLSTN3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:157,331,494...157,364,769
Ensembl chr 4:157,331,494...157,364,769
|
|
G |
Cntnap1 |
contactin associated protein 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CNTNAP1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:86,109,850...86,125,612
Ensembl chr10:86,111,643...86,125,611
|
|
G |
Comt |
catechol-O-methyltransferase |
decreases expression multiple interactions |
ISO |
butylbenzyl phthalate results in decreased expression of COMT mRNA fulvestrant inhibits the reaction [butylbenzyl phthalate results in decreased expression of COMT mRNA] |
CTD |
PMID:24040167 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CRH mRNA |
CTD |
PMID:32518293 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CRHR1 mRNA |
CTD |
PMID:32518293 |
|
NCBI chr10:89,040,203...89,083,481
Ensembl chr10:89,040,203...89,083,481
|
|
G |
Crmp1 |
collapsin response mediator protein 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CRMP1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:73,509,933...73,556,192
Ensembl chr14:73,509,933...73,556,177
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases acetylation affects localization |
ISO |
HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate affects the localization of CTNNB1 protein]; trichostatin A inhibits the reaction [butylbenzyl phthalate affects the localization of CTNNB1 protein] butylbenzyl phthalate results in increased acetylation of CTNNB1 protein |
CTD |
PMID:22552774 PMID:27923775 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
increases expression multiple interactions |
EXP ISO |
butylbenzyl phthalate results in increased expression of CYP11A1 mRNA; butylbenzyl phthalate results in increased expression of CYP11A1 protein [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CYP11A1 mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CYP11A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with 4-nonylphenol co-treated with 4-tert-octylphenol] results in decreased expression of CYP11A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP11A1 mRNA; [Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:26472102 PMID:28013214 PMID:29029336 PMID:30802670 PMID:31319113 PMID:32518293 PMID:34597818 More...
|
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of CYP11B1 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of CYP11B2 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions decreases expression |
ISO EXP |
[Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with 4-nonylphenol co-treated with 4-tert-octylphenol] results in increased expression of CYP17A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP17A1 mRNA butylbenzyl phthalate results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:26472102 PMID:29029336 PMID:30802670 PMID:33983380 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases expression decreases activity multiple interactions |
ISO |
butylbenzyl phthalate results in decreased expression of CYP19A1 mRNA; butylbenzyl phthalate results in decreased expression of CYP19A1 protein butylbenzyl phthalate results in decreased activity of CYP19A1 protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CYP19A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with 4-nonylphenol co-treated with 4-tert-octylphenol] results in decreased expression of CYP19A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with 4-nonylphenol co-treated with 4-tert-octylphenol] results in decreased expression of CYP19A1 protein; [Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP19A1 mRNA |
CTD |
PMID:27825933 PMID:28013214 PMID:29029336 PMID:34597818 |
|
NCBI chr 8:54,553,165...54,580,758
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression decreases activity |
ISO EXP |
butylbenzyl phthalate results in increased expression of CYP1A1 protein butylbenzyl phthalate results in decreased activity of CYP1A1 protein |
CTD |
PMID:22138065 PMID:27432241 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
EXP |
butylbenzyl phthalate results in decreased activity of CYP1A2 protein |
CTD |
PMID:27432241 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions increases expression |
ISO |
3',4'-dimethoxyflavone inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP1B1 mRNA]; 3',4'-dimethoxyflavone inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP1B1 protein]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP1B1 mRNA]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP1B1 protein]; butylbenzyl phthalate promotes the reaction [AHR protein binds to CYP1B1 promoter] butylbenzyl phthalate results in increased expression of CYP1B1 mRNA; butylbenzyl phthalate results in increased expression of CYP1B1 protein |
CTD |
PMID:22138065 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of CYP27A1 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
increases expression decreases activity |
ISO EXP |
butylbenzyl phthalate results in increased expression of CYP2B10 mRNA butylbenzyl phthalate results in decreased activity of CYP2B1 protein |
CTD |
PMID:26519955 PMID:27432241 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases activity |
EXP |
butylbenzyl phthalate results in decreased activity of CYP2C11 protein |
CTD |
PMID:27432241 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
EXP |
butylbenzyl phthalate results in decreased activity of CYP2E1 protein |
CTD |
PMID:27432241 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases activity |
EXP |
butylbenzyl phthalate results in decreased activity of CYP3A62 protein |
CTD |
PMID:27432241 |
|
NCBI chr12:16,397,998...16,433,833
Ensembl chr12:16,397,998...16,433,833
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of CYP51 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Dclk3 |
doublecortin-like kinase 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DCLK3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:111,401,544...111,453,999
Ensembl chr 8:111,401,358...111,453,999
|
|
G |
Ddc |
dopa decarboxylase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DDC mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of DHCR7 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dock3 |
dedicator of cyto-kinesis 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DOCK3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:107,552,462...107,903,527
Ensembl chr 8:107,552,463...107,903,514
|
|
G |
Dpf1 |
double PHD fingers 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DPF1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:84,602,212...84,615,954
Ensembl chr 1:84,602,336...84,615,950
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DYNC1I1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of EBP mRNA |
CTD |
PMID:26472102 |
|
NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826
|
|
G |
Ece2 |
endothelin-converting enzyme 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ECE2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:80,259,130...80,299,685
Ensembl chr11:80,263,162...80,278,428
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EDN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Edn2 |
endothelin 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of EDN2 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 5:133,751,316...133,756,814
Ensembl chr 5:133,751,217...133,756,814
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation |
ISO |
fulvestrant inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of EGFR protein] |
CTD |
PMID:22552774 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Elmod1 |
ELMO domain containing 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ELMOD1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:54,298,363...54,355,348
Ensembl chr 8:54,298,363...54,355,140
|
|
G |
Emx2 |
empty spiracles homeobox 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EMX2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:258,626,584...258,633,594
Ensembl chr 1:258,626,584...258,633,594
|
|
G |
Epdr1 |
ependymin related 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EPDR1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:45,333,677...45,358,597
Ensembl chr17:45,333,956...45,358,594
|
|
G |
Espn |
espin |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ESPN mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:162,626,560...162,660,439
Ensembl chr 5:162,626,560...162,660,256
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases methylation decreases expression increases activity multiple interactions affects binding |
ISO |
butylbenzyl phthalate results in decreased methylation of ESR1 gene; butylbenzyl phthalate results in decreased methylation of ESR1 promoter butylbenzyl phthalate results in decreased expression of ESR1 mRNA; butylbenzyl phthalate results in decreased expression of ESR1 protein butylbenzyl phthalate results in increased activity of ESR1 protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ESR1 mRNA butylbenzyl phthalate binds to ESR1 protein butylbenzyl phthalate binds to and results in increased activity of ESR1 protein; butylbenzyl phthalate inhibits the reaction [Estradiol results in increased activity of ESR1 protein]; Oxygen deficiency promotes the reaction [butylbenzyl phthalate results in decreased expression of ESR1 mRNA]; Oxygen deficiency promotes the reaction [butylbenzyl phthalate results in decreased expression of ESR1 protein]; Tamoxifen inhibits the reaction [butylbenzyl phthalate binds to and results in increased activity of ESR1 protein] |
CTD |
PMID:15840436 PMID:16326419 PMID:19913605 PMID:20822795 PMID:22467034 PMID:22949852 PMID:28013214 PMID:28571686 PMID:29162470 PMID:30851587 PMID:33049310 More...
|
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases activity affects binding |
ISO |
butylbenzyl phthalate binds to and results in decreased activity of ESR2 protein; butylbenzyl phthalate binds to and results in increased activity of ESR2 protein; butylbenzyl phthalate inhibits the reaction [Estradiol results in increased activity of ESR2 protein] [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ESR2 mRNA butylbenzyl phthalate results in increased activity of ESR2 protein butylbenzyl phthalate binds to ESR2 protein |
CTD |
PMID:15840436 PMID:19913605 PMID:28571686 PMID:32518293 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions increases expression |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of FABP4 mRNA butylbenzyl phthalate results in increased expression of FABP4 mRNA |
CTD |
PMID:24155963 PMID:26820058 PMID:27923775 PMID:34520170 |
|
NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FABP5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Fam163a |
family with sequence similarity 163, member A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FAM163A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:68,262,867...68,341,323
Ensembl chr13:68,262,872...68,341,049
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of FASN mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of FASN protein |
CTD |
PMID:26820058 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fez1 |
fasciculation and elongation protein zeta 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FEZ1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:36,544,462...36,589,684
Ensembl chr 8:36,544,535...36,589,683
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of FGFR2 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FKBP1B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:27,832,128...27,850,600
Ensembl chr 6:27,838,802...27,848,653
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of FKBP5 mRNA |
CTD |
PMID:32518293 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Flg |
filaggrin |
multiple interactions |
ISO |
[FLG gene polymorphism affects the susceptibility to butylbenzyl phthalate] which affects the abundance of mono-benzyl phthalate |
CTD |
PMID:24380925 |
|
NCBI chr 2:178,888,688...178,912,731
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
butylbenzyl phthalate results in increased expression of and results in increased acetylation of FOXO1 protein |
CTD |
PMID:27923775 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Fsd2 |
fibronectin type III and SPRY domain containing 2 |
increases expression decreases expression |
EXP |
butylbenzyl phthalate results in increased expression of FSD2 mRNA butylbenzyl phthalate results in decreased expression of FSD2 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 1:135,484,002...135,522,517
Ensembl chr 1:135,489,266...135,522,472
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
increases expression multiple interactions |
EXP ISO |
butylbenzyl phthalate results in increased expression of FSHB protein [Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of FSHB protein butylbenzyl phthalate promotes the reaction [Dibutyl Phthalate results in increased expression of FSHB protein] |
CTD |
PMID:29969652 PMID:34597818 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions increases expression |
ISO EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FSHR mRNA butylbenzyl phthalate results in increased expression of FSHR mRNA; butylbenzyl phthalate results in increased expression of FSHR protein |
CTD |
PMID:28013214 PMID:31319113 |
|
NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785
|
|
G |
Fxyd7 |
FXYD domain-containing ion transport regulator 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FXYD7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:86,277,678...86,286,954
Ensembl chr 1:86,277,678...86,286,954
|
|
G |
Gabpb1 |
GA binding protein transcription factor subunit beta 1 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of GABPB1 mRNA |
CTD |
PMID:26520405 |
|
NCBI chr 3:113,879,972...113,924,744
Ensembl chr 3:113,879,973...113,923,696
|
|
G |
Gfra3 |
GDNF family receptor alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GFRA3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:26,297,828...26,326,105
Ensembl chr18:26,297,829...26,326,105
|
|
G |
Gfra4 |
GDNF family receptor alpha 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GFRA4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:118,254,937...118,262,252
Ensembl chr 3:118,255,402...118,258,329
|
|
G |
Ggta1 |
glycoprotein alpha-galactosyltransferase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GGTA1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:18,732,985...18,824,916
Ensembl chr 3:18,732,991...18,809,908
|
|
G |
Gng2 |
G protein subunit gamma 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GNG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:4,316,038...4,416,918
Ensembl chr15:4,316,059...4,417,183
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GPX1 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Grb14 |
growth factor receptor bound protein 14 |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of GRB14 mRNA |
CTD |
PMID:15728792 |
|
NCBI chr 3:49,568,210...49,683,805
Ensembl chr 3:49,568,210...49,683,889
|
|
G |
Greb1 |
growth regulating estrogen receptor binding 1 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of GREB1 mRNA |
CTD |
PMID:35307500 |
|
NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIN2B mRNA |
CTD |
PMID:32518293 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation multiple interactions |
ISO |
butylbenzyl phthalate results in increased phosphorylation of GSK3B protein HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:22552774 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GSR mRNA |
CTD |
PMID:28013214 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GSTA3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
H19 |
H19 imprinted maternally expressed transcript |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of H19 mRNA |
CTD |
PMID:33395283 |
|
NCBI chr 1:197,730,698...197,733,374
Ensembl chr 1:197,730,698...197,733,134
|
|
G |
Hdac6 |
histone deacetylase 6 |
increases response to substance increases expression multiple interactions |
ISO |
HDAC6 results in increased susceptibility to butylbenzyl phthalate butylbenzyl phthalate results in increased expression of HDAC6 mRNA; butylbenzyl phthalate results in increased expression of HDAC6 protein [butylbenzyl phthalate promotes the reaction [TFAP2A protein binds to HDAC6 promoter]] which results in increased expression of HDAC6 mRNA; butylbenzyl phthalate promotes the reaction [TFAP2A protein binds to HDAC6 promoter]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate affects the localization of CTNNB1 protein]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in decreased expression of KRT7 protein]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of VIM protein]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of AKT1 protein]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of GSK3B protein]; TFAP2A mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of HDAC6 protein] |
CTD |
PMID:22552774 |
|
NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441
|
|
G |
Hey1 |
hes-related family bHLH transcription factor with YRPW motif 1 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of HEY1 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 2:93,096,706...93,100,316
Ensembl chr 2:93,095,498...93,100,312
|
|
G |
Hnf1a |
HNF1 homeobox A |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of HNF1A mRNA |
CTD |
PMID:15728792 |
|
NCBI chr12:41,638,536...41,672,806
Ensembl chr12:41,645,587...41,672,104
|
|
G |
Hoxb8 |
homeo box B8 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HOXB8 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:81,248,313...81,251,261
Ensembl chr10:81,248,887...81,250,638
|
|
G |
Hoxd3 |
homeo box D3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HOXD3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:59,638,708...59,650,282
Ensembl chr 3:59,638,708...59,650,282
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of HSD11B1 protein |
CTD |
PMID:31319113 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Hsd17b11 |
hydroxysteroid (17-beta) dehydrogenase 11 |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of HSD17B11 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr14:5,693,304...5,743,157
Ensembl chr14:5,711,964...5,743,161
|
|
G |
Hsd17b8 |
hydroxysteroid (17-beta) dehydrogenase 8 |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of HSD17B8 mRNA |
CTD |
PMID:19560483 PMID:26472102 |
|
NCBI chr20:4,826,725...4,828,742
Ensembl chr20:4,822,026...4,828,742
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions increases expression |
ISO EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HSD3B1 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of HSD3B1 mRNA butylbenzyl phthalate results in increased expression of HSD3B1 mRNA; butylbenzyl phthalate results in increased expression of HSD3B1 protein |
CTD |
PMID:28013214 PMID:31319113 PMID:35762964 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsd3b3 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 3 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of HSD3B3 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 2:186,138,044...186,144,024
Ensembl chr 2:186,138,044...186,144,033
|
|
G |
Hspa12a |
heat shock protein family A (Hsp70) member 12A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HSPA12A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:257,935,642...258,096,602
Ensembl chr 1:257,935,644...258,096,846
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of HTR1A mRNA |
CTD |
PMID:32518293 |
|
NCBI chr 2:36,694,174...36,695,442
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of HTR2A mRNA |
CTD |
PMID:32518293 |
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of ID1 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Ido2 |
indoleamine 2,3-dioxygenase 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of IDO2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr16:67,459,158...67,498,052
Ensembl chr16:67,459,190...67,496,324
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of IGF1 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igfbp7 |
insulin-like growth factor binding protein 7 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of IGFBP7 mRNA |
CTD |
PMID:19560483 |
|
NCBI chr14:30,737,414...30,797,317
Ensembl chr14:30,737,164...30,797,314
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of IL6 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inha |
inhibin subunit alpha |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of INHA mRNA |
CTD |
PMID:26472102 PMID:33983380 |
|
NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] affects the abundance of diphosphoric acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of carbamic acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Cholesterol analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Cystathionine analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Desmosterol analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of ethylamine analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Glycine analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Inositol analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of methylphosphate analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of monoethyl phosphate analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of n-butylamine analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Palmitic Acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of phosphoric acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Pyrrolidonecarboxylic Acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of sebacic acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of stearic acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of undecane analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of ACACA protein; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of ADIPOQ mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of ADIPOQ protein; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of CEBPA mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of CEBPA protein; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of CFD mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of FABP4 mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of FASN mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of FASN protein; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of LPL mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of PLIN1 protein; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of PPARG mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of PPARG protein; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Triglycerides]; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TNF mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Triglycerides]]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TNF mRNA]] butylbenzyl phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased secretion of TNFRSF11B protein]; butylbenzyl phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; butylbenzyl phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]; butylbenzyl phthalate promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein] |
CTD |
PMID:26820058 PMID:28595985 PMID:31016361 PMID:32407875 PMID:34864131 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insig1 |
insulin induced gene 1 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of INSIG1 mRNA |
CTD |
PMID:15728792 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Insl3 |
insulin-like 3 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of INSL3 mRNA |
CTD |
PMID:14687758 PMID:16102138 PMID:18411233 PMID:33983380 |
|
NCBI chr16:18,398,682...18,400,566
Ensembl chr16:18,384,829...18,400,560
|
|
G |
Irs1 |
insulin receptor substrate 1 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of IRS1 mRNA |
CTD |
PMID:33395283 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Kif5c |
kinesin family member 5C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of KIF5C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:34,032,082...34,185,597
Ensembl chr 3:34,032,105...34,182,413
|
|
G |
Krt7 |
keratin 7 |
decreases expression multiple interactions |
ISO |
butylbenzyl phthalate results in decreased expression of KRT7 protein HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in decreased expression of KRT7 protein] |
CTD |
PMID:22552774 |
|
NCBI chr 7:132,528,863...132,545,052
Ensembl chr 7:132,528,895...132,545,052
|
|
G |
L1cam |
L1 cell adhesion molecule |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of L1CAM mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:151,597,270...151,623,776
Ensembl chr X:151,597,277...151,623,857
|
|
G |
Lamp3 |
lysosomal-associated membrane protein 3 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of LAMP3 mRNA |
CTD |
PMID:20678512 |
|
NCBI chr11:81,153,491...81,224,643
Ensembl chr11:81,193,649...81,221,784
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LCN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Ldlr |
low density lipoprotein receptor |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of LDLR mRNA |
CTD |
PMID:15728792 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
multiple interactions |
ISO |
butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]]; trichostatin A inhibits the reaction [butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]] |
CTD |
PMID:22552774 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
decreases expression increases expression |
EXP |
butylbenzyl phthalate results in decreased expression of LHCGR mRNA butylbenzyl phthalate results in increased expression of LHCGR mRNA; butylbenzyl phthalate results in increased expression of LHCGR protein |
CTD |
PMID:15728792 PMID:31319113 |
|
NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521
|
|
G |
Lonrf2 |
LON peptidase N-terminal domain and ring finger 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LONRF2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:41,033,125...41,070,551
Ensembl chr 9:41,034,628...41,070,649
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of LPL mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of LPL mRNA |
CTD |
PMID:26820058 PMID:30768133 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrrc4b |
leucine rich repeat containing 4B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LRRC4B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:94,922,034...94,956,309
Ensembl chr 1:94,935,603...94,956,263
|
|
G |
Lynx1 |
Ly6/neurotoxin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LYNX1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:106,632,800...106,638,003
Ensembl chr 7:106,632,797...106,638,023
|
|
G |
Map6 |
microtubule-associated protein 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MAP6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:153,568,019...153,634,415
Ensembl chr 1:153,568,368...153,634,414
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
EXP |
butylbenzyl phthalate results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:31319113 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
EXP |
butylbenzyl phthalate results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:31319113 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MAPT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mc2r |
melanocortin 2 receptor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of MC2R mRNA |
CTD |
PMID:32518293 |
|
NCBI chr18:62,001,980...62,015,567
Ensembl chr18:62,004,948...62,015,488
|
|
G |
Mir107 |
microRNA 107 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of MIR107 mRNA |
CTD |
PMID:33395283 |
|
NCBI chr 1:232,337,767...232,337,853
Ensembl chr 1:232,337,767...232,337,853
|
|
G |
Mir141 |
microRNA 141 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR141 |
CTD |
PMID:31199487 |
|
NCBI chr 4:157,523,239...157,523,332
Ensembl chr 4:157,523,239...157,523,332
|
|
G |
Mir15b |
microRNA 15b |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of MIR15B mRNA |
CTD |
PMID:31629899 |
|
NCBI chr 2:153,245,200...153,245,297
Ensembl chr 2:153,245,200...153,245,297
|
|
G |
Mir184 |
microRNA 184 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR184; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR184 mRNA |
CTD |
PMID:31199487 PMID:35762964 |
|
NCBI chr 8:90,343,134...90,343,210
Ensembl chr 8:90,343,134...90,343,210
|
|
G |
Mir19a |
microRNA 19a |
multiple interactions increases expression |
ISO |
MIR19A mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of CDKN1A protein]; MIR19A mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of PTEN protein]; MIR19A mRNA affects the reaction [butylbenzyl phthalate results in increased expression of CCND1 protein]; MIR19A mRNA affects the reaction [butylbenzyl phthalate results in increased expression of PCNA protein] butylbenzyl phthalate results in increased expression of MIR19A mRNA |
CTD |
PMID:29864457 |
|
NCBI chr15:92,180,912...92,180,993
Ensembl chr15:92,180,912...92,180,993
|
|
G |
Mir19b1 |
microRNA 19b-1 |
multiple interactions increases expression |
ISO |
MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of CDKN1A protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of PTEN protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in increased expression of CCND1 protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in increased expression of PCNA protein] butylbenzyl phthalate results in increased expression of MIR19B1 mRNA |
CTD |
PMID:29864457 |
|
NCBI chr15:92,181,214...92,181,300
Ensembl chr15:92,181,214...92,181,300
|
|
G |
Mir34a |
microRNA 34a |
multiple interactions increases expression decreases expression |
ISO |
MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in decreased expression of CDKN1A protein]; MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of CCND1 protein]; MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of MYC protein]; MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of PCNA protein] MIR34A mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of NAMPT protein] butylbenzyl phthalate results in increased expression of MIR34A mRNA butylbenzyl phthalate results in decreased expression of MIR34A mRNA |
CTD |
PMID:30243731 PMID:34520170 |
|
NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103
|
|
G |
Mirlet7a1 |
microRNA let-7a-1 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of MIRLET7A-1 mRNA |
CTD |
PMID:33395283 |
|
NCBI chr17:16,113,766...16,113,859
Ensembl chr17:16,113,768...16,113,867
|
|
G |
Mirlet7b |
microRNA let-7b |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of MIRLET7B mRNA |
CTD |
PMID:33395283 |
|
NCBI chr 7:116,804,186...116,804,270
Ensembl chr 7:116,804,186...116,804,270
|
|
G |
Mirlet7c1 |
microRNA let-7c-1 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of MIRLET7C-1 mRNA |
CTD |
PMID:33395283 |
|
NCBI chr11:16,201,163...16,201,256
Ensembl chr11:16,201,158...16,201,265
|
|
G |
Mirlet7d |
microRNA let-7d |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of MIRLET7D mRNA |
CTD |
PMID:33395283 |
|
NCBI chr17:16,115,893...16,115,990
Ensembl chr17:16,115,893...16,115,990
|
|
G |
Mirlet7f-1 |
microRNA let7f-1 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of MIRLET7F-1 mRNA |
CTD |
PMID:33395283 |
|
NCBI chr17:16,114,130...16,114,226
Ensembl chr17:16,114,130...16,114,226
|
|
G |
Mllt11 |
MLLT11, transcription factor 7 cofactor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MLLT11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP14 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp16 |
matrix metallopeptidase 16 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP16 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 5:31,312,280...31,556,276
Ensembl chr 5:31,312,280...31,548,388
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions increases expression |
ISO |
ZEB1 protein affects the reaction [butylbenzyl phthalate results in increased expression of MMP2 protein] |
CTD |
PMID:31212022 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression multiple interactions |
ISO |
butylbenzyl phthalate results in increased expression of MMP9 protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of MMP9 mRNA] |
CTD |
PMID:31212022 PMID:33316053 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Msh2 |
mutS homolog 2 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of MSH2 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions increases expression |
ISO |
MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of MYC protein] butylbenzyl phthalate results in increased expression of MYC mRNA; butylbenzyl phthalate results in increased expression of MYC protein |
CTD |
PMID:30243731 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myocd |
myocardin |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of MYOCD mRNA |
CTD |
PMID:26472102 |
|
NCBI chr10:49,833,219...49,928,806
Ensembl chr10:49,836,641...49,927,627
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
decreases expression multiple interactions |
ISO |
butylbenzyl phthalate results in decreased expression of NAMPT mRNA; butylbenzyl phthalate results in decreased expression of NAMPT protein MIR34A mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of NAMPT protein] |
CTD |
PMID:34520170 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Ncs1 |
neuronal calcium sensor 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NCS1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:14,523,220...14,568,829
Ensembl chr 3:14,523,220...14,568,829
|
|
G |
Ndrg4 |
NDRG family member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NDRG4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:9,351,408...9,387,398
Ensembl chr19:9,351,404...9,386,914
|
|
G |
Nefh |
neurofilament heavy chain |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NEFH mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Nefl |
neurofilament light chain |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NEFL mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nell1 |
neural EGFL like 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NELL1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:99,709,305...100,573,872
Ensembl chr 1:99,709,793...100,573,860
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of NFE2L2 mRNA |
CTD |
PMID:27923775 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfil3 |
nuclear factor, interleukin 3 regulated |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of NFIL3 mRNA |
CTD |
PMID:15728792 |
|
NCBI chr17:12,280,499...12,295,728
Ensembl chr17:12,280,484...12,295,858
|
|
G |
Ngfr |
nerve growth factor receptor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NGFR mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of NR0B1 mRNA |
CTD |
PMID:15728792 PMID:33983380 |
|
NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases activity |
ISO |
butylbenzyl phthalate binds to and results in increased activity of NR1I2 protein butylbenzyl phthalate results in increased activity of NR1I2 protein |
CTD |
PMID:27551952 PMID:33049310 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
affects binding increases activity |
ISO |
butylbenzyl phthalate binds to NR1I3 protein butylbenzyl phthalate results in increased activity of NR1I3 protein; butylbenzyl phthalate results in increased activity of NR1I3 protein alternative form |
CTD |
PMID:25938866 PMID:27551952 PMID:28927721 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of NR3C1 mRNA |
CTD |
PMID:32518293 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NR3C2 mRNA |
CTD |
PMID:32518293 |
|
NCBI chr19:30,715,648...31,059,885
Ensembl chr19:30,715,648...31,059,885
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of NR4A3 mRNA |
CTD |
PMID:19560483 |
|
NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of NRF1 mRNA |
CTD |
PMID:26520405 PMID:27923775 |
|
NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Nrxn2 |
neurexin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NRXN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:203,726,420...203,842,301
Ensembl chr 1:203,735,753...203,842,297
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of NSDHL mRNA |
CTD |
PMID:19560483 |
|
NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142
|
|
G |
Nsg1 |
neuronal vesicle trafficking associated 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NSG1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:72,648,771...72,670,521
Ensembl chr14:72,648,741...72,670,514
|
|
G |
Nsg2 |
neuronal vesicle trafficking associated 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NSG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:15,601,594...15,661,441
Ensembl chr10:15,601,596...15,661,441
|
|
G |
Olfm1 |
olfactomedin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of OLFM1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:11,520,522...11,558,240
Ensembl chr 3:11,520,729...11,558,239
|
|
G |
Oxt |
oxytocin/neurophysin I prepropeptide |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of OXT mRNA |
CTD |
PMID:32518293 |
|
NCBI chr 3:117,782,650...117,783,490
Ensembl chr 3:117,782,650...117,783,490
|
|
G |
Oxtr |
oxytocin receptor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of OXTR mRNA |
CTD |
PMID:32518293 |
|
NCBI chr 4:145,598,549...145,614,674
Ensembl chr 4:145,599,561...145,614,674
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions increases expression |
ISO |
MIR19A mRNA affects the reaction [butylbenzyl phthalate results in increased expression of PCNA protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in increased expression of PCNA protein]; MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of PCNA protein] butylbenzyl phthalate results in increased expression of PCNA mRNA; butylbenzyl phthalate results in increased expression of PCNA protein |
CTD |
PMID:29864457 PMID:30243731 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pcp4 |
Purkinje cell protein 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PCP4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:35,759,711...35,861,725
Ensembl chr11:35,800,713...35,861,725
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression multiple interactions |
ISO |
butylbenzyl phthalate results in increased expression of PDK4 protein butylbenzyl phthalate results in increased expression of and results in increased stability of PDK4 mRNA |
CTD |
PMID:31629899 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pdp2 |
pyruvate dehydrogenase phosphatase catalytic subunit 2 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of PDP2 mRNA |
CTD |
PMID:31629899 |
|
NCBI chr19:386,408...394,068
Ensembl chr19:386,406...394,074
|
|
G |
Pgr |
progesterone receptor |
increases expression multiple interactions |
EXP ISO |
butylbenzyl phthalate results in increased expression of PGR mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PGR mRNA] |
CTD |
PMID:11474214 PMID:33316053 PMID:35307500 |
|
NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PLAT mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plin1 |
perilipin 1 |
multiple interactions increases expression |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of PLIN1 protein butylbenzyl phthalate results in increased expression of PLIN1 protein |
CTD |
PMID:26820058 PMID:34520170 |
|
NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828
|
|
G |
Plppr3 |
phospholipid phosphatase related 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PLPPR3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:9,831,162...9,842,434
Ensembl chr 7:9,831,162...9,845,296
|
|
G |
Pls1 |
plastin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PLS1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:96,316,703...96,426,592
Ensembl chr 8:96,317,849...96,385,195
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects binding multiple interactions |
ISO |
butylbenzyl phthalate binds to PPARA protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PPARA mRNA |
CTD |
PMID:23843199 PMID:28013214 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
affects binding |
ISO |
butylbenzyl phthalate binds to PPARB protein |
CTD |
PMID:23843199 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases activity increases expression affects binding |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of PPARG mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of PPARG protein; butylbenzyl phthalate binds to and results in increased activity of PPARG protein; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]]; PPARG protein promotes the reaction [butylbenzyl phthalate binds to and results in increased activity of PPARG protein] butylbenzyl phthalate results in increased activity of PPARG protein butylbenzyl phthalate results in increased expression of PPARG mRNA butylbenzyl phthalate binds to PPARG protein butylbenzyl phthalate binds to and results in increased activity of PPARG protein; butylbenzyl phthalate inhibits the reaction [GW 1929 binds to PPARG protein] |
CTD |
PMID:23843199 PMID:24155963 PMID:26172262 PMID:26820058 PMID:27923775 PMID:28595985 PMID:31016361 PMID:32407875 PMID:33049310 PMID:34520170 More...
|
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression affects expression |
ISO |
butylbenzyl phthalate results in decreased expression of PPARGC1A mRNA butylbenzyl phthalate affects the expression of PPARGC1A mRNA |
CTD |
PMID:26520405 PMID:27923775 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppp2r2b |
protein phosphatase 2, regulatory subunit B, beta |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PPP2R2B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:34,653,716...35,080,889
Ensembl chr18:34,653,721...35,081,025
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PRIMA1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:122,338,365...122,390,955
Ensembl chr 6:122,338,370...122,389,921
|
|
G |
Prph |
peripherin |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PRPH mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:130,218,149...130,222,136
Ensembl chr 7:130,218,357...130,222,136
|
|
G |
Pten |
phosphatase and tensin homolog |
decreases expression multiple interactions |
ISO |
butylbenzyl phthalate results in decreased expression of PTEN mRNA; butylbenzyl phthalate results in decreased expression of PTEN protein MIR19A mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of PTEN protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of PTEN protein] |
CTD |
PMID:29864457 |
|
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTGES mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTGR1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PTGS2 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptprn |
protein tyrosine phosphatase, receptor type, N |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTPRN mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:76,741,010...76,756,704
Ensembl chr 9:76,741,016...76,756,190
|
|
G |
Qsox1 |
quiescin sulfhydryl oxidase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of QSOX1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:67,949,780...67,987,434
Ensembl chr13:67,949,780...67,987,459
|
|
G |
Rab3b |
RAB3B, member RAS oncogene family |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:123,629,562...123,697,410
Ensembl chr 5:123,644,423...123,697,401
|
|
G |
Rab6b |
RAB6B, member RAS oncogene family |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB6B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:103,695,328...103,764,023
Ensembl chr 8:103,695,631...103,805,732
|
|
G |
Rassf4 |
Ras association domain family member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RASSF4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:149,897,525...149,932,658
Ensembl chr 4:149,897,543...149,932,411
|
|
G |
Resp18 |
regulated endocrine-specific protein 18 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RESP18 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:76,765,179...76,771,824
Ensembl chr 9:76,764,590...76,778,722
|
|
G |
Rnf183 |
ring finger protein 183 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of RNF183 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:75,877,111...75,886,253
Ensembl chr 5:75,876,003...75,886,191
|
|
G |
Rtn1 |
reticulon 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RTN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:90,763,212...90,983,436
Ensembl chr 6:90,763,216...90,983,436
|
|
G |
Rtn4r |
reticulon 4 receptor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RTN4R mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:82,844,585...82,869,012
Ensembl chr11:82,844,309...82,869,466
|
|
G |
Rxra |
retinoid X receptor alpha |
affects binding |
ISO |
butylbenzyl phthalate binds to RXRA protein |
CTD |
PMID:23843199 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Rxrb |
retinoid X receptor beta |
affects binding |
ISO |
butylbenzyl phthalate binds to RXRB protein |
CTD |
PMID:23843199 |
|
NCBI chr20:4,816,813...4,823,267
Ensembl chr20:4,816,815...4,828,773
|
|
G |
Rxrg |
retinoid X receptor gamma |
affects binding |
ISO |
butylbenzyl phthalate binds to RXRG protein |
CTD |
PMID:23843199 |
|
NCBI chr13:79,743,430...79,785,173
Ensembl chr13:79,743,563...79,785,167
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of SCARB1 mRNA; butylbenzyl phthalate results in decreased expression of SCARB1 protein |
CTD |
PMID:26472102 PMID:31319113 PMID:33983380 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Scg3 |
secretogranin III |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCG3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:76,399,777...76,442,015
Ensembl chr 8:76,399,777...76,442,015
|
|
G |
Scn3b |
sodium voltage-gated channel beta subunit 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCN3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:40,630,372...40,652,869
Ensembl chr 8:40,630,455...40,652,868
|
|
G |
Scrn1 |
secernin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCRN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:83,632,125...83,694,225
Ensembl chr 4:83,632,131...83,693,852
|
|
G |
Serpinb2 |
serpin family B member 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINB2 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sh3gl3 |
SH3 domain containing GRB2 like 3, endophilin A3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SH3GL3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:136,124,502...136,255,669
Ensembl chr 1:136,124,499...136,255,584
|
|
G |
Sh3tc2 |
SH3 domain and tetratricopeptide repeats 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SH3TC2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:55,416,383...55,477,419
Ensembl chr18:55,416,413...55,483,083
|
|
G |
Shbg |
sex hormone binding globulin |
affects binding |
ISO |
butylbenzyl phthalate binds to SHBG protein |
CTD |
PMID:25349334 |
|
NCBI chr10:54,332,939...54,350,409
Ensembl chr10:54,332,941...54,351,057
|
|
G |
Shc2 |
SHC adaptor protein 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SHC2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:10,066,705...10,088,926
Ensembl chr 7:10,066,705...10,088,926
|
|
G |
Sirt1 |
sirtuin 1 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of SIRT1 mRNA; butylbenzyl phthalate results in decreased expression of SIRT1 protein |
CTD |
PMID:26520405 PMID:27923775 PMID:34520170 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sirt3 |
sirtuin 3 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of SIRT3 mRNA; butylbenzyl phthalate results in decreased expression of SIRT3 protein |
CTD |
PMID:26520405 PMID:27923775 PMID:34520170 |
|
NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Sirt7 |
sirtuin 7 |
decreases expression affects expression |
ISO |
butylbenzyl phthalate results in decreased expression of SIRT7 mRNA butylbenzyl phthalate affects the expression of SIRT7 mRNA |
CTD |
PMID:27923775 PMID:31016965 |
|
NCBI chr10:105,896,476...105,903,301
Ensembl chr10:105,896,476...105,903,172
|
|
G |
Slc13a2 |
solute carrier family 13 member 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC13A2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:63,291,813...63,319,127
Ensembl chr10:63,291,815...63,319,127
|
|
G |
Slc29a4 |
solute carrier family 29 member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC29A4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr12:11,853,540...11,884,660
Ensembl chr12:11,853,540...11,874,834
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
increases expression |
ISO EXP |
butylbenzyl phthalate results in increased expression of SLC5A5 mRNA |
CTD |
PMID:16257484 |
|
NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697
|
|
G |
Slc5a7 |
solute carrier family 5 member 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC5A7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:7,595,440...7,626,258
Ensembl chr 9:7,595,444...7,626,258
|
|
G |
Slco2a1 |
solute carrier organic anion transporter family, member 2a1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of SLCO2A1 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 8:103,588,916...103,672,546
Ensembl chr 8:103,588,916...103,672,546
|
|
G |
Smim24 |
small integral membrane protein 24 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SMIM24 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:8,310,530...8,316,686
|
|
G |
Snhg11 |
small nucleolar RNA host gene 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SNHG11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:147,031,411...147,037,809
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SOD1 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sohlh2 |
spermatogenesis and oogenesis specific basic helix-loop-helix 2 |
increases expression multiple interactions decreases expression |
EXP |
butylbenzyl phthalate results in increased expression of SOHLH2 mRNA 4-vinyl-1-cyclohexene dioxide inhibits the reaction [butylbenzyl phthalate results in increased expression of SOHLH2 mRNA]; [4-vinyl-1-cyclohexene dioxide co-treated with butylbenzyl phthalate] results in decreased expression of SOHLH2 protein butylbenzyl phthalate results in decreased expression of SOHLH2 protein |
CTD |
PMID:29969652 |
|
NCBI chr 2:139,362,246...139,384,700
Ensembl chr 2:139,362,246...139,384,699
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
decreases expression increases expression |
EXP |
butylbenzyl phthalate results in decreased expression of SOX9 mRNA butylbenzyl phthalate results in increased expression of SOX9 mRNA; butylbenzyl phthalate results in increased expression of SOX9 protein |
CTD |
PMID:26472102 PMID:31319113 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Sp1 |
Sp1 transcription factor |
decreases expression multiple interactions |
ISO |
butylbenzyl phthalate results in decreased expression of SP1 mRNA [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with 4-nonylphenol co-treated with 4-tert-octylphenol] results in decreased expression of SP1 mRNA |
CTD |
PMID:29029336 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
increases phosphorylation multiple interactions |
ISO |
butylbenzyl phthalate results in increased phosphorylation of SRC protein fulvestrant inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of SRC protein] |
CTD |
PMID:22552774 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Srd5a1 |
steroid 5 alpha-reductase 1 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of SRD5A1 mRNA |
CTD |
PMID:19560483 |
|
NCBI chr 1:33,686,069...33,720,468
Ensembl chr 1:33,686,391...33,720,461
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression multiple interactions increases expression |
ISO EXP |
butylbenzyl phthalate results in decreased expression of STAR mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of STAR mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STAR mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with 4-nonylphenol co-treated with 4-tert-octylphenol] results in increased expression of STAR mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of STAR mRNA; [Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of STAR mRNA butylbenzyl phthalate results in increased expression of STAR mRNA butylbenzyl phthalate results in decreased expression of STAR mRNA; butylbenzyl phthalate results in decreased expression of STAR protein |
CTD |
PMID:19560483 PMID:26472102 PMID:28013214 PMID:29029336 PMID:30802670 PMID:31319113 PMID:33983380 PMID:34597818 PMID:35762964 More...
|
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stk32c |
serine/threonine kinase 32C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STK32C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:193,900,718...193,981,723
Ensembl chr 1:193,900,718...193,981,723
|
|
G |
Stmn4 |
stathmin 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STMN4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:40,541,305...40,559,253
Ensembl chr15:40,541,357...40,559,253
|
|
G |
Syt11 |
synaptotagmin 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SYT11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:174,206,032...174,232,540
Ensembl chr 2:174,206,191...174,231,964
|
|
G |
Syt5 |
synaptotagmin 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SYT5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:69,277,351...69,285,071
Ensembl chr 1:69,277,351...69,285,067
|
|
G |
Tbx2 |
T-box transcription factor 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TBX2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:70,679,670...70,688,868
Ensembl chr10:70,679,518...70,688,529
|
|
G |
Tcf21 |
transcription factor 21 |
increases expression decreases expression |
EXP |
butylbenzyl phthalate results in increased expression of TCF21 mRNA butylbenzyl phthalate results in decreased expression of TCF21 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 1:22,701,353...22,704,212
Ensembl chr 1:22,701,353...22,704,202
|
|
G |
Tcf23 |
transcription factor 23 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TCF23 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:25,397,889...25,406,639
Ensembl chr 6:25,397,937...25,405,880
|
|
G |
Tcf4 |
transcription factor 4 |
multiple interactions |
ISO |
butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]]; trichostatin A inhibits the reaction [butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]] |
CTD |
PMID:22552774 |
|
NCBI chr18:62,941,739...63,288,126
Ensembl chr18:62,943,782...63,284,425
|
|
G |
Tcte1 |
t-complex-associated testis expressed 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TCTE1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:15,463,573...15,482,258
Ensembl chr 9:15,463,739...15,472,954
|
|
G |
Tfam |
transcription factor A, mitochondrial |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of TFAM mRNA |
CTD |
PMID:27923775 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Tfap2a |
transcription factor AP-2 alpha |
affects localization multiple interactions |
ISO |
butylbenzyl phthalate affects the localization of TFAP2A protein [butylbenzyl phthalate promotes the reaction [TFAP2A protein binds to HDAC6 promoter]] which results in increased expression of HDAC6 mRNA; butylbenzyl phthalate promotes the reaction [TFAP2A protein binds to HDAC6 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [butylbenzyl phthalate affects the localization of TFAP2A protein]; RTKI cpd inhibits the reaction [butylbenzyl phthalate affects the localization of TFAP2A protein]; TFAP2A mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of HDAC6 protein] |
CTD |
PMID:22552774 |
|
NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of TFF1 mRNA |
CTD |
PMID:35307500 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of THY1 protein |
CTD |
PMID:22552774 |
|
NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of TIMP1 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tmeff2 |
transmembrane protein with EGF-like and two follistatin-like domains 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEFF2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:50,445,550...50,733,482
Ensembl chr 9:50,436,079...50,733,475
|
|
G |
Tmem130 |
transmembrane protein 130 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM130 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr12:9,837,055...9,862,843
Ensembl chr12:9,837,055...9,862,840
|
|
G |
Tmem35a |
transmembrane protein 35A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM35A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:97,503,350...97,514,198
Ensembl chr X:97,503,350...97,514,197
|
|
G |
Tmem63c |
transmembrane protein 63c |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM63C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:106,667,389...106,738,778
Ensembl chr 6:106,672,934...106,736,990
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
butylbenzyl phthalate inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TNF mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TNF mRNA]] |
CTD |
PMID:15256756 PMID:28595985 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
ISO |
butylbenzyl phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased secretion of TNFRSF11B protein] |
CTD |
PMID:31016361 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tp53 |
tumor protein p53 |
increases methylation decreases expression |
ISO |
butylbenzyl phthalate results in increased methylation of TP53 promoter butylbenzyl phthalate results in decreased expression of TP53 mRNA |
CTD |
PMID:35487445 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TRPC6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092
|
|
G |
Ttyh1 |
tweety family member 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TTYH1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:70,053,312...70,071,872
Ensembl chr 1:70,053,324...70,071,845
|
|
G |
Tubb2b |
tubulin, beta 2B class IIb |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB2B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:30,747,734...30,750,781
Ensembl chr17:30,747,734...30,750,638
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
|
|
G |
Tubb4a |
tubulin, beta 4A class IVa |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB4A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:1,917,841...1,925,286
Ensembl chr 9:1,917,845...1,925,291
|
|
G |
Ubash3b |
ubiquitin associated and SH3 domain containing, B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of UBASH3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:41,385,419...41,532,248
Ensembl chr 8:41,388,341...41,532,201
|
|
G |
Ubxn11 |
UBX domain protein 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of UBXN11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:146,329,666...146,353,529
Ensembl chr 5:146,329,842...146,353,526
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions decreases secretion increases secretion |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [butylbenzyl phthalate results in increased secretion of VEGFA protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [butylbenzyl phthalate results in increased secretion of VEGFA protein]; butylbenzyl phthalate promotes the reaction [Oxygen deficiency results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [butylbenzyl phthalate results in increased secretion of VEGFA protein]; Wortmannin inhibits the reaction [butylbenzyl phthalate results in increased secretion of VEGFA protein] butylbenzyl phthalate results in decreased secretion of VEGFA protein |
CTD |
PMID:18252963 PMID:25016925 PMID:30851587 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
multiple interactions increases expression |
ISO |
butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of VIM protein]; trichostatin A inhibits the reaction [butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]] |
CTD |
PMID:22552774 PMID:31212022 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Wnt4 |
Wnt family member 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of WNT4 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 5:149,513,573...149,535,415
Ensembl chr 5:149,514,018...149,532,859
|
|
G |
Wnt6 |
Wnt family member 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WNT6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:76,329,882...76,343,523
Ensembl chr 9:76,329,882...76,343,523
|
|
G |
Wnt9b |
Wnt family member 9B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WNT9B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:88,635,330...88,657,035
Ensembl chr10:88,635,331...88,657,035
|
|
G |
Wt1 |
WT1 transcription factor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WT1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643
|
|
G |
Zcchc12 |
zinc finger CCHC-type containing 12 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ZCCHC12 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:115,433,444...115,436,691
Ensembl chr X:115,433,259...115,436,692
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
multiple interactions increases expression increases stability |
ISO |
butylbenzyl phthalate results in increased expression of and results in increased stability of ZEB1 mRNA; MIR655 mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of ZEB1 mRNA]; ZEB1 protein affects the reaction [butylbenzyl phthalate results in increased expression of MMP2 protein] butylbenzyl phthalate results in increased expression of ZEB1 protein ATM protein affects the reaction [butylbenzyl phthalate results in increased expression of ZEB1 protein]; butylbenzyl phthalate results in increased expression of and affects the localization of ZEB1 protein; butylbenzyl phthalate results in increased expression of and results in increased stability of ZEB1 mRNA; MIR655 mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of ZEB1 protein]; ZEB1 protein affects the reaction [butylbenzyl phthalate results in increased expression of MMP2 protein] butylbenzyl phthalate results in increased stability of ZEB1 protein |
CTD |
PMID:31212022 |
|
NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214
|
|
G |
Zfat |
zinc finger and AT hook domain containing |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ZFAT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:99,886,954...100,054,288
Ensembl chr 7:99,886,954...100,054,274
|
|
G |
Zp2 |
zona pellucida glycoprotein 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ZP2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:174,513,507...174,525,288
Ensembl chr 1:174,513,511...174,525,288
|
|
|
G |
Cd69 |
Cd69 molecule |
decreases localization |
ISO |
capsiate analog results in decreased localization of CD69 protein |
CTD |
PMID:12115659 |
|
NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases localization |
ISO |
capsiate analog results in decreased localization of ICAM1 protein |
CTD |
PMID:12115659 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases expression |
ISO |
capsiate results in increased expression of IGF1 protein |
CTD |
PMID:17307377 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Ikbkg |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
multiple interactions |
ISO |
capsiate analog inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Plant Preparations] results in increased activity of IKBKG protein] |
CTD |
PMID:12115659 |
|
NCBI chr X:152,216,485...152,241,476
Ensembl chr X:152,216,596...152,239,499
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
decreases localization |
ISO |
capsiate analog results in decreased localization of IL2RA protein |
CTD |
PMID:12115659 |
|
NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
capsiate analog inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Plant Preparations] results in increased degradation of NFKBIA protein] |
CTD |
PMID:12115659 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ucp3 |
uncoupling protein 3 |
decreases expression |
EXP |
capsiate results in decreased expression of UCP3 mRNA |
CTD |
PMID:17264228 |
|
NCBI chr 1:154,815,777...154,828,764
Ensembl chr 1:154,815,777...154,828,762
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB protein]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 protein]; CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]; CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]; CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]; CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB protein]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]] |
CTD |
PMID:25446015 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions |
EXP ISO |
[CGP 42112A binds to and results in increased activity of AGTR2 protein] which affects the susceptibility to Phenylephrine; [CGP 42112A binds to and results in increased activity of AGTR2 protein] which results in increased abundance of and results in increased secretion of Triglycerides; [CGP 42112A binds to and results in increased activity of AGTR2 protein] which results in increased abundance of Fatty Acids, Nonesterified; CGP 42112A binds to and results in increased activity of AGTR2 protein CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]; CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]] |
CTD |
PMID:16003179 PMID:19151255 PMID:25446015 |
|
NCBI chr X:112,119,673...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Agtrap |
angiotensin II receptor-associated protein |
multiple interactions |
ISO |
CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]; CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]] |
CTD |
PMID:25446015 |
|
NCBI chr 5:158,507,427...158,519,036
Ensembl chr 5:158,508,749...158,519,036
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB protein]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB protein]] |
CTD |
PMID:25446015 |
|
NCBI chr X:13,360,583...13,392,517
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions |
ISO |
CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]] |
CTD |
PMID:25446015 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
ISO |
CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 protein]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]] |
CTD |
PMID:25446015 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Ube2v2 |
ubiquitin conjugating enzyme E2 V2 |
increases expression |
EXP |
CGP 42112A results in increased expression of UBE2V2 mRNA; CGP 42112A results in increased expression of UBE2V2 protein |
CTD |
PMID:17068200 |
|
NCBI chr11:85,304,528...85,338,430
Ensembl chr11:85,304,526...85,336,369
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity multiple interactions |
ISO |
crotoxyphos results in decreased activity of ACHE protein [crotoxyphos co-treated with Dichlorvos] results in decreased activity of ACHE protein |
CTD |
PMID:4859365 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
benzohydrol binds to and results in increased activity of ESR1 protein |
CTD |
PMID:16079615 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
benzohydrol binds to and results in increased activity of ESR2 protein |
CTD |
PMID:16079615 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases oxidation |
ISO |
AKR1B10 protein results in increased oxidation of 1-indanol |
CTD |
PMID:19013440 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
Ku 0063794 results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:22885370 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
[Ku 0063794 co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in decreased phosphorylation of EIF4EBP1 protein; [Ku 0063794 co-treated with AZD 6244] results in decreased phosphorylation of EIF4EBP1 protein; [Ku 0063794 co-treated with mirdametinib] results in decreased phosphorylation of EIF4EBP1 protein; Ku 0063794 inhibits the reaction [dactolisib results in decreased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:22415236 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Rps6 |
ribosomal protein S6 |
multiple interactions decreases phosphorylation |
ISO |
[Ku 0063794 co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in decreased phosphorylation of RPS6 protein Ku 0063794 results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:22415236 PMID:22885370 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
affects expression multiple interactions |
ISO |
mono-benzyl phthalate affects the expression of AHR mRNA [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] affects the expression of AHR mRNA |
CTD |
PMID:28381288 PMID:31884101 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ahrr |
aryl-hydrocarbon receptor repressor |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] affects the expression of AHRR mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 1:28,993,634...29,088,673
Ensembl chr 1:28,993,634...29,088,673
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of AIFM1 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
mono-benzyl phthalate promotes the reaction [Dihydrotestosterone results in increased activity of AR protein] [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of AR mRNA |
CTD |
PMID:28571686 PMID:31884101 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] affects the expression of ARNT mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of BAX mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression decreases methylation |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] affects the expression of BCL2 mRNA mono-benzyl phthalate results in increased expression of BCL2 mRNA mono-benzyl phthalate results in decreased methylation of BCL2 promoter |
CTD |
PMID:31884101 PMID:35487445 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l10 |
Bcl2-like 10 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of BCL2L10 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 8:76,107,326...76,113,373
Ensembl chr 8:76,107,326...76,113,367
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of BID mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bok |
BCL2 family apoptosis regulator BOK |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of BOK mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 9:94,223,493...94,234,476
Ensembl chr 9:94,223,389...94,234,476
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CASP3 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CASP8 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of CAT mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
mono-benzyl phthalate results in increased expression of CCL2 mRNA |
CTD |
PMID:32015430 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CCNA2 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CCNB1 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnb2 |
cyclin B2 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CCNB2 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression decreases methylation |
ISO |
mono-benzyl phthalate results in increased expression of CCND1 mRNA mono-benzyl phthalate results in decreased methylation of CCND1 promoter |
CTD |
PMID:35487445 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd3 |
cyclin D3 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CCND3 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CCNE1 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
multiple interactions |
ISO |
[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-benzyl phthalate co-treated with monobutyl phthalate] results in increased expression of CCR7 mRNA |
CTD |
PMID:30398665 |
|
NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309
|
|
G |
Cd163 |
CD163 molecule |
multiple interactions |
ISO |
[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-benzyl phthalate co-treated with monobutyl phthalate] results in decreased expression of CD163 mRNA |
CTD |
PMID:30398665 |
|
NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878
|
|
G |
Cd36 |
CD36 molecule |
increases expression multiple interactions |
ISO |
mono-benzyl phthalate results in increased expression of CD36 mRNA GW 6471 inhibits the reaction [mono-benzyl phthalate results in increased expression of CD36 mRNA] |
CTD |
PMID:35421560 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd68 |
Cd68 molecule |
increases expression |
ISO |
mono-benzyl phthalate results in increased expression of CD68 mRNA |
CTD |
PMID:32015430 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CDK2 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CDK4 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of CDKN1A mRNA |
CTD |
PMID:31884101 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CDKN1B mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CDKN1C mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions increases methylation decreases expression |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of CDKN2A mRNA mono-benzyl phthalate results in increased methylation of CDKN2A promoter mono-benzyl phthalate results in decreased expression of CDKN2A mRNA |
CTD |
PMID:31884101 PMID:35487445 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of CDKN2B mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CDKN2C mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Cdkn2d |
cyclin dependent kinase inhibitor 2D |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] affects the expression of CDKN2D mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 8:19,831,874...19,834,640
Ensembl chr 8:19,831,866...19,834,674
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
increases expression affects expression increases secretion |
ISO |
mono-benzyl phthalate results in increased expression of CGA mRNA mono-benzyl phthalate affects the expression of CGA mRNA mono-benzyl phthalate results in increased secretion of CGA protein |
CTD |
PMID:28381288 PMID:29089286 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Crp |
C-reactive protein |
increases expression |
ISO |
mono-benzyl phthalate results in increased expression of CRP protein |
CTD |
PMID:21349512 |
|
NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-benzyl phthalate co-treated with monobutyl phthalate] results in increased expression of CXCL10 mRNA |
CTD |
PMID:30398665 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions affects expression increases expression |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CYP11A1 mRNA mono-benzyl phthalate affects the expression of CYP11A1 mRNA mono-benzyl phthalate results in increased expression of CYP11A1 mRNA |
CTD |
PMID:28381288 PMID:29089286 PMID:31884101 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
affects expression multiple interactions |
ISO |
mono-benzyl phthalate affects the expression of CYP19A1 mRNA [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CYP19A1 mRNA |
CTD |
PMID:28381288 PMID:31884101 |
|
NCBI chr 8:54,553,165...54,580,758
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of CYP1A1 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CYP1B1 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity |
EXP |
mono-benzyl phthalate results in decreased activity of CYP2B1 protein |
CTD |
PMID:27432241 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases activity |
EXP |
mono-benzyl phthalate results in decreased activity of CYP3A62 protein |
CTD |
PMID:27432241 |
|
NCBI chr12:16,397,998...16,433,833
Ensembl chr12:16,397,998...16,433,833
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
mono-benzyl phthalate results in increased expression of EREG mRNA |
CTD |
PMID:29089286 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
mono-benzyl phthalate promotes the reaction [Estradiol results in increased activity of ESR1 protein] [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of ESR1 mRNA |
CTD |
PMID:28571686 PMID:31884101 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
mono-benzyl phthalate promotes the reaction [Estradiol results in increased activity of ESR2 protein] [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of ESR2 mRNA |
CTD |
PMID:28571686 PMID:31884101 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions increases expression |
ISO |
T 0070907 inhibits the reaction [mono-benzyl phthalate results in increased expression of FABP4 mRNA] |
CTD |
PMID:35421560 |
|
NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Flg |
filaggrin |
multiple interactions |
ISO |
[FLG gene polymorphism affects the susceptibility to butylbenzyl phthalate] which affects the abundance of mono-benzyl phthalate |
CTD |
PMID:24380925 |
|
NCBI chr 2:178,888,688...178,912,731
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of FSHR mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of GPX1 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of GSR mRNA |
CTD |
PMID:31884101 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hsd17b1 |
hydroxysteroid (17-beta) dehydrogenase 1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of HSD17B1 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr10:86,009,728...86,011,928
Ensembl chr10:86,009,728...86,011,927
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of HSD3B1 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-benzyl phthalate co-treated with monobutyl phthalate] results in increased expression of IL6 mRNA |
CTD |
PMID:30398665 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of LHCGR mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of MKI67 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-benzyl phthalate co-treated with monobutyl phthalate] results in increased secretion of MMP9 protein |
CTD |
PMID:30398665 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
multiple interactions |
ISO |
[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-benzyl phthalate co-treated with monobutyl phthalate] results in decreased expression of MRC1 mRNA |
CTD |
PMID:30398665 |
|
NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
mono-benzyl phthalate results in increased activity of NR1I2 protein |
CTD |
PMID:27551952 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity multiple interactions |
ISO |
mono-benzyl phthalate results in increased activity of NR1I3 protein alternative form [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of NR1I3 mRNA |
CTD |
PMID:27551952 PMID:31884101 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects binding multiple interactions increases activity |
ISO |
mono-benzyl phthalate binds to PPARA protein [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of PPARA mRNA mono-benzyl phthalate results in increased activity of PPARA protein |
CTD |
PMID:23843199 PMID:27551952 PMID:31884101 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
affects binding multiple interactions increases activity |
ISO |
mono-benzyl phthalate binds to PPARB protein [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of PPARD mRNA mono-benzyl phthalate results in increased activity of PPARD protein |
CTD |
PMID:23843199 PMID:27551952 PMID:31884101 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects binding increases expression increases activity multiple interactions |
ISO |
mono-benzyl phthalate binds to PPARG protein mono-benzyl phthalate results in increased expression of PPARG protein mono-benzyl phthalate results in increased activity of PPARG protein [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of PPARG mRNA |
CTD |
PMID:23843199 PMID:27551952 PMID:29089286 PMID:31884101 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
affects expression |
ISO |
mono-benzyl phthalate affects the expression of PTGS2 mRNA |
CTD |
PMID:29089286 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Shbg |
sex hormone binding globulin |
multiple interactions decreases secretion |
ISO |
[Phthalic Acids results in increased abundance of mono-benzyl phthalate] which results in increased expression of and results in increased secretion of SHBG protein mono-benzyl phthalate results in decreased secretion of SHBG protein |
CTD |
PMID:24945889 PMID:28637469 |
|
NCBI chr10:54,332,939...54,350,409
Ensembl chr10:54,332,941...54,351,057
|
|
G |
Skp2 |
S-phase kinase associated protein 2 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of SKP2 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 2:58,161,226...58,189,293
Ensembl chr 2:58,161,229...58,189,338
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of STAR mRNA |
CTD |
PMID:31884101 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
ISO |
mono-benzyl phthalate results in increased expression of TNF mRNA |
CTD |
PMID:32015430 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases methylation decreases expression |
ISO |
mono-benzyl phthalate results in increased methylation of TP53 promoter mono-benzyl phthalate results in decreased expression of TP53 mRNA |
CTD |
PMID:35487445 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Pnlip |
pancreatic lipase |
decreases activity |
ISO |
4-hydroxybenzyl alcohol results in decreased activity of PNLIP protein |
CTD |
PMID:30273962 |
|
NCBI chr 1:257,774,012...257,811,656
Ensembl chr 1:257,798,581...257,811,654
|
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
increases activity |
ISO |
ractopamine results in increased activity of ADRB2 protein |
CTD |
PMID:34601065 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
ractopamine binds to and results in increased activity of ESR1 protein |
CTD |
PMID:24928891 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
ractopamine results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases expression |
ISO |
Ritodrine results in increased expression of ABCC4 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Adk |
adenosine kinase |
decreases expression |
ISO |
Ritodrine results in decreased expression of ADK mRNA |
CTD |
PMID:23370008 |
|
NCBI chr15:2,863,241...3,246,453
Ensembl chr15:2,863,244...3,246,510
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
Ritodrine results in increased expression of ASNS mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
decreases expression |
ISO |
Ritodrine results in decreased expression of AVPR1A mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215
|
|
G |
Ccn1 |
cellular communication network factor 1 |
increases expression |
ISO |
Ritodrine results in increased expression of CCN1 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
Ritodrine results in increased expression of CD36 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Csad |
cysteine sulfinic acid decarboxylase |
decreases expression |
ISO |
Ritodrine results in decreased expression of CSAD mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 7:133,308,571...133,337,914
Ensembl chr 7:133,308,574...133,337,615
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
decreases expression |
ISO |
Ritodrine results in decreased expression of CYP51 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
decreases expression |
ISO |
Ritodrine results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dbp |
D-box binding PAR bZIP transcription factor |
increases expression |
ISO |
Ritodrine results in increased expression of DBP mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
increases expression |
ISO |
Ritodrine results in increased expression of ELOVL6 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
|
|
G |
Errfi1 |
ERBB receptor feedback inhibitor 1 |
decreases expression |
ISO |
Ritodrine results in decreased expression of ERRFI1 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282
|
|
G |
Foxa3 |
forkhead box A3 |
decreases expression |
ISO |
Ritodrine results in decreased expression of FOXA3 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 1:78,662,067...78,672,321
Ensembl chr 1:78,662,431...78,672,155
|
|
G |
G0s2 |
G0/G1switch 2 |
decreases expression |
ISO |
Ritodrine results in decreased expression of G0S2 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr13:104,806,351...104,807,263
Ensembl chr13:104,806,156...104,807,451
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
decreases expression |
ISO |
Ritodrine results in decreased expression of GADD45G mRNA |
CTD |
PMID:23370008 |
|
NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
increases expression |
ISO |
Ritodrine results in increased expression of GSTM3 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 2:195,531,627...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
decreases expression |
ISO |
Ritodrine results in decreased expression of HSD17B7 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
decreases expression |
ISO |
Ritodrine results in decreased expression of IDI1 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357
|
|
G |
Ins2 |
insulin 2 |
increases expression |
ISO |
Ritodrine results in increased expression of INS protein |
CTD |
PMID:356601 PMID:3883263 PMID:9186877 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Ip6k2 |
inositol hexakisphosphate kinase 2 |
increases expression |
ISO |
Ritodrine results in increased expression of IP6K2 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 8:109,483,843...109,510,172
Ensembl chr 8:109,484,310...109,510,166
|
|
G |
Klf10 |
KLF transcription factor 10 |
decreases expression |
ISO |
Ritodrine results in decreased expression of KLF10 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
ISO |
Ritodrine results in increased expression of LCN2 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
increases expression |
ISO |
Ritodrine results in increased expression of MAP2K6 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
decreases expression |
ISO |
Ritodrine results in decreased expression of MSMO1 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016
|
|
G |
Mt2A |
metallothionein 2A |
increases expression |
ISO |
Ritodrine results in increased expression of MT2 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mthfr |
methylenetetrahydrofolate reductase |
decreases expression |
ISO |
Ritodrine results in decreased expression of MTHFR mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797
|
|
G |
Per3 |
period circadian regulator 3 |
increases expression |
ISO |
Ritodrine results in increased expression of PER3 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 5:161,460,228...161,495,404
Ensembl chr 5:161,459,533...161,495,607
|
|
G |
Prom1 |
prominin 1 |
increases expression |
ISO |
Ritodrine results in increased expression of PROM1 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527
|
|
G |
Qpct |
glutaminyl-peptide cyclotransferase |
decreases expression |
ISO |
Ritodrine results in decreased expression of QPCT mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 6:15,964,656...15,996,925
Ensembl chr 6:15,964,657...15,996,711
|
|
G |
Ren |
renin |
increases activity |
ISO |
Ritodrine results in increased activity of REN protein |
CTD |
PMID:31167 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Rtn4rl1 |
reticulon 4 receptor-like 1 |
decreases expression |
ISO |
Ritodrine results in decreased expression of RTN4RL1 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr10:60,043,246...60,116,977
Ensembl chr10:60,043,002...60,116,978
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
ISO |
Ritodrine results in increased expression of SCD1 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Serpina12 |
serpin family A member 12 |
decreases expression |
ISO |
Ritodrine results in decreased expression of SERPINA12 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 6:122,952,552...122,967,271
Ensembl chr 6:122,952,552...122,967,271
|
|
G |
Serpina4 |
serpin family A member 4 |
decreases expression |
ISO |
Ritodrine results in decreased expression of SERPINA4-PS1 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 6:122,999,970...123,009,083
Ensembl chr 6:122,999,900...123,009,082
|
|
G |
Slc30a10 |
solute carrier family 30, member 10 |
decreases expression |
ISO |
Ritodrine results in decreased expression of SLC30A10 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr13:96,998,143...97,048,076
Ensembl chr13:96,998,143...97,009,103
|
|
G |
Slc41a2 |
solute carrier family 41 member 2 |
increases expression |
ISO |
Ritodrine results in increased expression of SLC41A2 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 7:20,383,714...20,491,178
Ensembl chr 7:20,383,757...20,491,166
|
|
G |
Snx5 |
sorting nexin 5 |
decreases expression |
ISO |
Ritodrine results in decreased expression of SNX5 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 3:131,621,709...131,641,205
Ensembl chr 3:131,621,880...131,641,192
|
|
G |
Sqle |
squalene epoxidase |
decreases expression |
ISO |
Ritodrine results in decreased expression of SQLE mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases phosphorylation |
ISO |
Ritodrine results in increased phosphorylation of STAT3 protein |
CTD |
PMID:23370008 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tbx3 |
T-box transcription factor 3 |
decreases expression |
ISO |
Ritodrine results in decreased expression of TBX3 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr12:36,879,924...36,894,849
Ensembl chr12:36,881,445...36,893,708
|
|
G |
Thrsp |
thyroid hormone responsive |
increases expression |
ISO |
Ritodrine results in increased expression of THRSP mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075
|
|
G |
Tsc22d1 |
TSC22 domain family, member 1 |
decreases expression |
ISO |
Ritodrine results in decreased expression of TSC22D1 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr15:51,750,489...51,850,958
Ensembl chr15:51,749,510...51,850,958
|
|
G |
Upp2 |
uridine phosphorylase 2 |
increases expression |
ISO |
Ritodrine results in increased expression of UPP2 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 3:43,273,048...43,317,417
Ensembl chr 3:43,273,048...43,317,417
|
|
G |
Usp2 |
ubiquitin specific peptidase 2 |
increases expression |
ISO |
Ritodrine results in increased expression of USP2 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 8:44,411,457...44,439,668
Ensembl chr 8:44,411,607...44,438,331
|
|
G |
Wee1 |
WEE1 G2 checkpoint kinase |
increases expression |
ISO |
Ritodrine results in increased expression of WEE1 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688
|
|
G |
Zfp318 |
zinc finger protein 318 |
increases expression |
ISO |
Ritodrine results in increased expression of ZFP318 mRNA |
CTD |
PMID:23370008 |
|
NCBI chr 9:14,562,958...14,601,557
Ensembl chr 9:14,563,313...14,601,409
|
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ALB protein binds to and affects the transport of salicin |
CTD |
PMID:8831264 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Tas2r118 |
taste receptor, type 2, member 118 |
multiple interactions increases activity |
ISO |
4-((diethylamino)sulfonyl)benzoic acid inhibits the reaction [salicin results in increased activity of TAS2R16 protein]; Probenecid inhibits the reaction [salicin results in increased activity of TAS2R16 protein] |
CTD |
PMID:21629661 |
|
NCBI chr 4:52,449,208...52,450,107
Ensembl chr 4:52,449,208...52,450,107
|
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ALB protein binds to and affects the transport of salicyl alcohol |
CTD |
PMID:8831264 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
ISO |
[2-(2-cresyl)-4H-1-3-2-benzodioxaphosphorin-2-oxide binds to and results in decreased activity of BCHE protein] which results in increased abundance of salicyl alcohol |
CTD |
PMID:22898212 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
salicyl alcohol inhibits the reaction [2,2'-azobis(2-amidinopropane) results in decreased activity of SOD2 protein] |
CTD |
PMID:19665455 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
|
G |
Or5d18 |
olfactory receptor family 5 subfamily D member 18 |
multiple interactions |
ISO |
vanillyl alcohol binds to and results in increased activity of OR5D18 protein |
CTD |
PMID:21142015 |
|
NCBI chr 3:73,516,522...73,517,463
Ensembl chr 3:73,516,364...73,519,858 Ensembl chr 3:73,516,364...73,519,858
|
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
increases activity |
ISO |
vilanterol results in increased activity of ADRB2 protein |
CTD |
PMID:34601065 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|